Therapeutic Vaccine Market to Reach $47.6 Billion by 2035

Therapeutic vaccine market is projected to grow from $17.1 billion in 2025 to $47.6 billion by 2035, registering a CAGR of 10.8% during the forecast period. Growth is primarily driven by the increasing burden of chronic diseases, particularly cancer, and rapid advancements in immunotherapy technologies.

Browse the full report description of “Therapeutic Vaccine Market Size, Share & Trends Analysis Report, By Vaccine Type (Cancer Therapeutic Vaccines, Infectious Disease Therapeutic Vaccines, Autoimmune Disease Vaccines, Neurological Disorder Vaccines), By Technology Platform (mRNA Vaccines, DNA Vaccines, Peptide/Protein-Based Vaccines, Dendritic Cell Vaccines, Viral Vector-Based Vaccines, Whole Cell Vaccines), By End User (Hospitals, Specialty Clinics, Research Institutes, Ambulatory Surgical Centers), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/therapeutic-vaccine-market

A key macro driver is the rising global cancer incidence. According to the World Health Organization (WHO), cancer caused nearly 10 million deaths in 2022, making it a leading global health concern. The growing patient pool is accelerating demand for advanced therapies such as cancer therapeutic vaccines, which activate the immune system to target tumour cells. Additionally, increasing clinical validation of mRNA-based therapies is boosting confidence in next-generation vaccine platforms. Recent studies indicate that mRNA cancer vaccines, when combined with immunotherapy, can significantly improve survival outcomes and immune response in cancer patients.

Among segments, Cancer Therapeutic Vaccines dominate and are the fastest-growing due to increasing adoption in oncology treatment protocols. Clinical trials across melanoma, pancreatic, and lung cancers have demonstrated strong immunogenicity and improved recurrence-free survival rates, positioning this segment as a key revenue contributor.

Recent Developments (2022–2026)

• In December 2022, Moderna and Merck & Co. reported that their personalized mRNA cancer vaccine mRNA-4157/V940, combined with KEYTRUDA, reduced the risk of recurrence or death by 44% in a Phase 2b melanoma trial. This marks the first successful randomized validation of an mRNA-based therapeutic cancer vaccine, supporting market growth.

• In 2025, a study published in Acta Naturae highlighted that mRNA-based personalized cancer vaccines are emerging as a promising therapeutic approach, demonstrating strong potential in treating cancers such as melanoma, lung, and breast cancer. Ongoing clinical trials and advancements in mRNA design and delivery technologies are expected to significantly enhance treatment efficacy and drive growth in the therapeutic vaccine market.

These strategic initiatives demonstrate a strong industry focus on innovation, partnerships, and pipeline expansion, particularly in mRNA and personalized vaccine technologies, which are expected to significantly accelerate market growth.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• By Product Type
• By Technology
• By End-User Industry
• Competitive Landscape –

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Therapeutic Vaccine Market Report Segment

By Vaccine Type

• Cancer Therapeutic Vaccines
• Infectious Disease Therapeutic Vaccines
• Autoimmune Disease Vaccines
• Neurological Disorder Vaccines

By Technology Platform

• mRNA Vaccines
• DNA Vaccines
• Peptide/Protein-Based Vaccines
• Dendritic Cell Vaccines
• Viral Vector-Based Vaccines
• Whole Cell Vaccines

By End User

• Hospitals
• Specialty Clinics (Oncology & Immunology Centers)
• Research Institutes
• Ambulatory Surgical Centers

Global Therapeutic Vaccine Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/therapeutic-vaccine-market